YC Biotech and Happy Taipei Community Health Care Group hosted a signing banquet on the 19th in Taipei City, marking the beginning of a collaboration aimed at introducing EG BioMed’s innovative DNA methylation breast cancer detection technology to the group’s network of clinics. This partnership is set to enhance early breast cancer detection with a more accurate and efficient testing solution.
As the exclusive agent for EG BioMed’s DNA methylation detection technology, YC Biotech brings extensive expertise in regulatory certification, contract manufacturing, product development, and commercialization strategies tailored for biotechnology companies. The signing banquet served as a key platform to promote this cutting-edge diagnostic tool to healthcare providers within the Happy Taipei Community Health Care Group, reinforcing the commitment to improving cancer diagnostics.
EG BioMed has long been at the forefront of developing early cancer detection, prognosis monitoring, and recurrence assessment technologies. Their DNA methylation detection method offers significant value for early-stage breast cancer diagnosis, providing a powerful tool for both patients and healthcare professionals.
During the event, YC Biotech formalized agreements with multiple clinics under the Happy Taipei Medical Group, enabling them to adopt EG BioMed’s advanced breast cancer detection technology. With this integration, clinics will be able to offer patients a state-of-the-art early detection method, improving both diagnostic accuracy and overall patient care.
This collaboration not only accelerates the adoption of DNA methylation breast cancer detection technology in Taipei but also equips Happy Taipei Community Health Care Group’s clinics with a more precise and reliable tool for cancer screening. The partnership underscores a shared commitment to delivering comprehensive and high-quality medical services, ultimately benefiting patients through earlier and more accurate cancer detection.
